Inovio Pharmaceuticals’ (INO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Inovio Pharmaceuticals (NASDAQ:INO – Free Report) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $5.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the stock. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price target (down from $8.00) on shares of Inovio Pharmaceuticals in a report on Wednesday. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research report on Wednesday. Finally, Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $6.33.

Read Our Latest Stock Analysis on INO

Inovio Pharmaceuticals Trading Down 2.1%

INO traded down $0.03 during midday trading on Thursday, hitting $1.43. The company’s stock had a trading volume of 5,176,647 shares, compared to its average volume of 27,271,350. The firm has a market cap of $157.56 million, a P/E ratio of -2.65 and a beta of 1.71. The firm has a 50-day moving average price of $1.18 and a two-hundred day moving average price of $1.27. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $2.27 million. On average, equities analysts expect that Inovio Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in INO. HighTower Advisors LLC grew its stake in shares of Inovio Pharmaceuticals by 104.8% during the third quarter. HighTower Advisors LLC now owns 26,076 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 13,346 shares in the last quarter. Headlands Technologies LLC purchased a new position in Inovio Pharmaceuticals in the second quarter valued at about $33,000. Engineers Gate Manager LP purchased a new position in Inovio Pharmaceuticals in the second quarter valued at about $37,000. Squarepoint Ops LLC grew its stake in Inovio Pharmaceuticals by 46.5% during the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,554 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC grew its stake in Inovio Pharmaceuticals by 312.4% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 53,510 shares in the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Featured Stories

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.